- Home
- SRL vs GALT Comparison
SRL vs GALT Comparison
Compare SRL & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRL | GALT |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.0M | 232.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SRL | GALT |
|---|---|---|
| Price | $6.32 | $6.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 9.9K | ★ 465.8K |
| Earning Date | 12-30-2025 | 11-14-2025 |
| Dividend Yield | ★ 16.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,535,042.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.13 | $0.73 |
| 52 Week High | $9.99 | $6.66 |
Technical Indicators
Market Signals| Indicator | SRL | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 59.79 |
| Support Level | $5.85 | $5.10 |
| Resistance Level | $6.36 | $6.32 |
| Average True Range (ATR) | 0.43 | 0.54 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 47.78 | 82.05 |
Price Performance
Historical ComparisonAbout SRL Scully Royalty Ltd.
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.